Clinical Scorecard: Patterns of Genetic Alterations and Prognostic Implications of Homologous Recombination Repair Genes in Gliomas
At a Glance
Category
Detail
Condition
Gliomas, primary malignant brain tumors
Key Mechanisms
Homologous recombination repair (HRR) pathway mutations leading to HRR loss of function (LOF) and homologous recombination deficiency (HRD)
Target Population
Patients with gliomas, including those with germline and somatic HRR gene mutations
Care Setting
Neuro-oncology clinical and research settings with genomic profiling capabilities
Key Highlights
HRR pathway mutations occur in gliomas and are classified into germline and somatic LOF mutations.
HRR LOF status correlates with molecular characteristics, tumor mutational burden, and immune microenvironment features.
Gliomas with HRR LOF may have distinct prognostic outcomes and potential sensitivity to targeted therapies such as PARP inhibitors.
Guideline-Based Recommendations
Diagnosis
Perform next-generation sequencing (NGS) using brain tumor gene panels to identify HRR gene mutations in glioma patients.
Classify HRR mutations as germline or somatic LOF based on pathogenicity and variant type.
Use RNA-seq and immune profiling to assess tumor immune microenvironment in HRR LOF gliomas.
Management
Consider HRR LOF status when evaluating therapeutic strategies, including potential use of PARP inhibitors and platinum-based chemotherapy.
Integrate molecular profiling results with clinical and histological data to guide personalized treatment approaches.
Monitoring & Follow-up
Monitor survival outcomes and disease progression in relation to HRR LOF mutation status.
Evaluate immune-related gene expression and immune cell infiltration as potential biomarkers during treatment.
Risks
HRR LOF mutations may confer increased genomic instability, influencing tumor aggressiveness and treatment resistance.
Potential for variable treatment response necessitates careful molecular characterization.
Patient & Prescribing Data
Glioma patients with identified HRR gene mutations (germline or somatic LOF)
Patients with HRR LOF mutations may benefit from therapies targeting DNA repair deficiencies, such as PARP inhibitors and platinum-based agents, although clinical validation in gliomas is ongoing.
Clinical Best Practices
Utilize comprehensive genomic panels covering HRR-related genes for accurate mutation detection in gliomas.
Incorporate both germline and somatic mutation analysis to fully characterize HRR LOF status.
Apply integrated bioinformatics pipelines for variant calling, annotation, and immune microenvironment assessment.
Use standardized statistical methods to correlate HRR LOF status with clinical outcomes and molecular features.
Consider multidisciplinary approaches combining molecular diagnostics, neuro-oncology, and immunology for optimal patient management.
